129 related articles for article (PubMed ID: 6758569)
1. Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma.
Konits PH; Van Echo DA; Aisner J; Morris D; Wiernik PH
Am J Clin Oncol; 1982 Oct; 5(5):515-9. PubMed ID: 6758569
[TBL] [Abstract][Full Text] [Related]
2. VP-16 and adriamycin in patients with advanced breast cancer.
Vaughn CB; Maniscalco-Greb E; Lockhard C; Groshko G; Enochs K; Duffin H; Demitrish M
Am J Clin Oncol; 1982 Oct; 5(5):505-9. PubMed ID: 6897491
[TBL] [Abstract][Full Text] [Related]
3. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
4. Etoposide (VP-16-213) and cis-dichlorodiammineplatinum (DDP) in advanced breast carcinoma resistant to previous chemotherapy.
Athanassiades P; Bacoyiannes H; Kontoyiannes D
Chemioterapia; 1986 Apr; 5(2):125-7. PubMed ID: 3518965
[TBL] [Abstract][Full Text] [Related]
5. [A phase I study of VP-16-213 (VP, etoposide) by single and 5-day intravenous administration].
Wakui A; Yokoyama M; Takahashi H; Yoshida Y; Sakata Y; Sato S; Kano A; Kawamoto K; Hashimoto S; Konno K
Gan To Kagaku Ryoho; 1986 Feb; 13(2):319-29. PubMed ID: 3947109
[TBL] [Abstract][Full Text] [Related]
6. Phase II evaluation of VP-16-213 in patients with advanced breast cancer: a Southwest Oncology Group Study.
Vaughn CB; Panettiere F; Thigpen T; Bottomley R; Hoogstraten B; Samal B
Cancer Treat Rep; 1981; 65(5-6):443-5. PubMed ID: 7237465
[No Abstract] [Full Text] [Related]
7. Evaluation of adriamycin and dibromodulcitol in metastatic breast carcinoma.
Tormey DC; Simon R; Falkson G; Bull J; Band P; Perlin E; Blom J
Cancer Res; 1977 Feb; 37(2):529-34. PubMed ID: 832277
[TBL] [Abstract][Full Text] [Related]
8. [Effects of oral etoposide in small cell carcinoma of the lung].
Miyamoto H; Ito M; Araya Y; Takaoka K; Isobe H; Dosaka H; Kawakami Y; Shimizu T; Onodera S
Gan To Kagaku Ryoho; 1984 Jun; 11(6):1244-7. PubMed ID: 6329103
[TBL] [Abstract][Full Text] [Related]
9. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP).
DiStefano A; Yap HY; Blumenschein GR
Cancer Treat Rep; 1981; 65(1-2):33-8. PubMed ID: 7013977
[TBL] [Abstract][Full Text] [Related]
11. A dose-seeking trial of edatrexate in combination with vinblastine, adriamycin, cisplatin, and filgrastim (EVAC/G-CSF) in patients with advanced malignancies: promising antineoplastic activity against non-small cell lung carcinomas.
Colón-Otero G; Marschke R; Camoriano JK; Sorensen JM; Sloan JA; Richardson RL
Cancer J Sci Am; 1997; 3(5):297-302. PubMed ID: 9327154
[TBL] [Abstract][Full Text] [Related]
12. Phase I study of VP-16-213 (Etoposide) administered as a continuous 5-day infusion.
Lokich J; Corkery J
Cancer Treat Rep; 1981; 65(9-10):887-9. PubMed ID: 7273024
[TBL] [Abstract][Full Text] [Related]
13. Intensive chemotherapy with cisplatin, doxorubicin, cyclophosphamide, etoposide and granulocyte colony-stimulating factor for advanced thymoma or thymic cancer: preliminary results.
Oshita F; Kasai T; Kurata T; Fukuda M; Yamamoto N; Ohe Y; Tamura T; Eguchi K; Shinkai T; Saijo N
Jpn J Clin Oncol; 1995 Oct; 25(5):208-12. PubMed ID: 7474409
[TBL] [Abstract][Full Text] [Related]
14. Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
Costanza ME; Berry D; Henderson IC; Ratain MJ; Wu K; Shapiro C; Duggan D; Kalra J; Berkowitz I; Lyss AP
Clin Cancer Res; 1995 Jul; 1(7):699-704. PubMed ID: 9816035
[TBL] [Abstract][Full Text] [Related]
15. Pegylated liposomal doxorubicin in combination with vinorelbine as salvage treatment in pretreated patients with advanced breast cancer: a multicentre phase II study.
Ardavanis A; Mavroudis D; Kalbakis K; Malamos N; Syrigos K; Vamvakas L; Kotsakis A; Kentepozidis N; Kouroussis C; Agelaki S; Georgoulias V;
Cancer Chemother Pharmacol; 2006 Dec; 58(6):742-8. PubMed ID: 16718470
[TBL] [Abstract][Full Text] [Related]
16. Effective remission induction of refractory childhood acute nonlymphocytic leukemia by VP-16-213 plus azacitidine.
Look AT; Dahl GV; Kalwinsky D; Senzer N; Mason C; Rivera G
Cancer Treat Rep; 1981; 65(11-12):995-9. PubMed ID: 6170431
[TBL] [Abstract][Full Text] [Related]
17. Paclitaxel and 5-fluorouracil in metastatic breast cancer: the US experience.
Paul DM; Garrett AM; Meshad M; DeVore RD; Porter LL; Johnson DH
Semin Oncol; 1996 Feb; 23(1 Suppl 1):48-52. PubMed ID: 8629038
[TBL] [Abstract][Full Text] [Related]
18. Phase II trial of doxorubicin, 5-fluorouracil, etoposide, and cisplatin in advanced or recurrent endometrial carcinoma.
Pierga JY; Diéras V; Beuzeboc P; Dorval T; Palangié T; Jouve M; Scholl SM; Garcia-Giralt E; Pouillart P
Gynecol Oncol; 1997 Aug; 66(2):246-9. PubMed ID: 9264570
[TBL] [Abstract][Full Text] [Related]
19. The sequential administration of combined doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Frassineti GL; Zoli W; Tienghi A; Ravaioli A; Milandri C; Gentile A; Salzano E; Amadori D
Semin Oncol; 1996 Oct; 23(5 Suppl 12):22-8. PubMed ID: 8941407
[TBL] [Abstract][Full Text] [Related]
20. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
Holmes FA
Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]